Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide

European Heart Journal

Volumn 23, Issue 24, 2002, Pages 1946-1954

  Willoughby, S R ^a   Stewart, S ^a   Chirkov, Y Y ^a   Kennedy, J A ^a   Holmes, A S ^a   Horowitz, John D ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Angina; cGMP; Nitric oxide; Perhexiline; Platelets

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GLYCERYL TRINITRATE; HEPARIN; NITRATE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PERHEXILINE; XANTHINE OXIDASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; BLOOD PLATELETS; CARDIOVASCULAR AGENTS; CORONARY DISEASE; CYCLIC GMP; FEMALE; HUMANS; MALE; NEUTROPHILS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; PERHEXILINE; PLATELET AGGREGATION; SUPEROXIDES;

EID: 0036899544     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3296     Document Type: Article

References (26)

1. Folts JD, Stamler J, Loscalzo J. Intravenous nitroglycerine infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation 1991; 83: 2122-7.
2. Chirkov YY, Holmes AS, Willoughby SR et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 2001; 37: 1851-7.
3. Chirkov YY, Holmes AS, Chirkova LP, Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 1999; 100: 129-34.
4. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
5. Woods JD, Edwards JS, Ritter JM. Inhibition by nitroprusside of platelet calcium mobilization: Evidence for reduced sensitivity to nitric oxide in essential hypertension. J Hypertens 1993; 11: 1369-73.
6. Verbeuren TJ, Coene MC, Jordaens FH, Van Hove CE, Zonnekeyn LL, Herman AG. Effect of hypercholesterolaemia on vascular reactivity in the rabbit. Influence of treatment with dipyridamole on endothelium-dependent and endothelium-independent responses in isolated aortas of control and hypercholesterolemic rabbits. Circ Res 1986; 59: 496-504.
7. Raitakari OT, Seale JP, Celermajer DS. Impaired vascular responses to nitroglycerine in subjects with coronary atherosclerosis. Am J Cardiol 2001; 87: 217-9.
8. Cole PL, Beamer AD, McGowan N et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
9. Horowitz JD, Button IK, Wing L. Is perhexiline essential for the optimal management of angina pectoris? Aust NZ J Med 1995; 25: 111-13.
10. Brown MJ, Horowitz JD, Mashford ML. A double-blind trial of perhexiline maleate in the prophylaxis of angina pectoris. Med J Aust 1976; 1: 260-3.
11. White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients with refractory to beta-adrenoceptor blockade. Int J Cardiol 1983; 3: 145-55.
12. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52: 273-80.
13. Stewart S, Voss DW, Northey DL, Horowitz JD. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit 1996; 18: 635-9.
14. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris: Correlations with pharmacokinetics. Int J Cardiol 1986; 13: 219-29.
15. Leo R, Pratico D, Iuliano L et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenation. Circulation 1997; 95: 885-91.
16. Skatchkov MP, Sperling D, Hink U et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochim Biophys Res Comm 1999; 254: 319-24.
17. Willoughby SR, Chirkov YY, Kennedy JA, Murphy GA, Chirkova LP, Horowitz JD. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol 1998; 356: 207-13.
18. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoriscorrelations with pharmacokinetics. Int J Cardiol 1986; 13: 219-29.
19. Horgan JH, O'Callaghan WG, Teo KK. Therapy of angina pectoris with low-dose perhexiline. J Cardiovasc Pharmacol 1981; 3: 566-72.
20. Chirkov YY, Chirkova LP, Horowitz JD. Nitroglycerine tolerance at the platelet level in patients with angina pectoris. Am J Cardiol 1997; 80: 128-31.
21. Sage PR, de la Lande IS, Stafford I et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102: 2810-5.
22. Luccioni R, Vague P, Luccioni F et al. Abnormalities of insulin secretion in coronary patients: Effects of perhexiline maleate. In: Perhexiline Maleate. Proceedings of A Symposium. Amsterdam: Excerpta Medica, 1978: 71-88.
23. Hubinger A, Weikert G, Wolf HP, Gries FA. The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Horm Metab Res 1992; 24: 115-8.
24. Sinha AK, Bhattacharya S, Acharya K, Mazumder S. Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo. Life Sci 1999; 65: 2687-96.
25. Cohen M, Demers C, Gurfinkel et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997; 337: 447-52.
26. The PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1487-97.